Equity Research Pharmaceutical Preparations

Should You Buy Prestige Consumer Healthcare In Stock in 2026?

By CirclFi Research Team · · 12/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Prestige Consumer Healthcare In (PBH) scores a robust 8.1/10 on our 32-signal Quality of Company framework. At the current market price of $49.02, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.

The short answer: 5 of 12 CirclFi valuation models project upside for Prestige Consumer Healthcare In (PBH) at $49.02 — the model consensus leans bearish, with a Quality Score of 8.1/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 7 of 12 models suggest overvaluation — majority bearish
  • Quality Score: 8.1/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 12/100 — Minimal — healthy fundamentals
  • Fair Value Range: $9.43 – $90.82 (863% spread)

Bullish Models

5 / 12

Bearish Models

7 / 12

Quality Score

8.1 /10

Excellent — top-tier fundamentals

Value Trap Risk

12 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

12 /13
Active Models

Avg. confidence: 54%

Investment Thesis

The Bull Case

Target: $90.82 (+85.3% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Prestige Consumer Healthcare In's quality score of 8.1/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
  • According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $90.82 (+85.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
  • Industry tailwind: regulatory pathway clarity could provide meaningful support for Prestige Consumer Healthcare In's revenue and margin trajectory in the Pharmaceutical Preparations space.

The Bear Case

Target: $9.43 (-80.8%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $9.43 (-80.8%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +166.0% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: clinical trial failure represents a meaningful risk for Prestige Consumer Healthcare In and its Pharmaceutical Preparations peers.

Peer Benchmarking

AZN AstraZeneca PLC
10.0
CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0
SIGA SIGA Technologies In
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

863%

Fair Value Range

$9.43 – $90.82

A 863% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

RCMH-DCF

$90.82 (+85.3%)

Most Bearish

Markov DDM

$9.43 (-80.8%)

Key Risk Factors

Model Disagreement

863% spread signals high variance in projections.

Bearish Consensus

7/12 models suggest overvaluation.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View PBH Data Page →

The Bottom Line

Prestige Consumer Healthcare In at $49.02 is a genuine coin-flip in our framework. The 5–5 bull-bear split across 12 models, +166.0% model spread, and composite fair value of $46.94 (-4.2% avg.) argue for a watchlist position rather than a high-conviction bet. Quality at 8.1/10 adds some comfort to the mix.

These are quantitative model outputs, not investment recommendations. Prestige Consumer Healthcare In's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy PBH stock right now?

Based on CirclFi's multi-model analysis, 5 of 12 models see upside for PBH at $49.02. The models are divided, which means the investment case depends heavily on your assumptions about Prestige Consumer Healthcare In's future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Prestige Consumer Healthcare In?

Key risks include: wide model disagreement (863% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does PBH compare to its competitors?

Among Pharmaceutical Preparations peers, PBH holds a Quality Score of 8.1/10. Comparable companies include AZN (QOC 10.0), CPRX (QOC 10.0), HRMY (QOC 10.0). The relative ranking helps investors identify whether PBH offers better fundamental quality than alternatives in the same sector.

Is PBH a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PBH's Quality Score of 8.1/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy PBH at?

CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $9.43 to $90.82. At $49.02, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for PBH.

View PBH Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →